CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 123 enrolled
Drug / intervention
Trifarotene Cream +1 moredrug
Likely dose
Trifarotene Cream 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05089708
NCT05089708Phase 4Completed
CompareCT.gov

Evaluation of Acne-induced Hyperpigmentation During Treatment of Acne Vulgaris Subjects With Trifarotene 50 μg/g Cream Versus Vehicle Cream Over 24 Weeks

Galderma R&D·interventional·Posted Oct 22, 2021·Updated Dec 20, 2023

In Brief

A Phase 4 clinical trial evaluating Trifarotene Cream and Trifarotene Vehicle Cream for Acne Vulgaris. Completed, enrolled 123 participants across 25 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesSpain, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedOct 22, 2021
Enrollment StartDec 22, 2021
Primary CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.7 years ago

Interventions

Trifarotene Creamdrug

Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks

Trifarotene Vehicle Creamdrug

Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks